Key result
Toronto SPV stentless porcine xenograft for AVR shows 0% valve-related mortality and near-normal performance.
Observational (n=14)
Preliminary experience with the Toronto SPV stentless porcine bioprosthesis for aortic valve replacement demonstrated safety with no valve-related mortality or morbidity and near normal early echocardiographic performance.
Answers are grounded in this paper and cite their sources.
Preliminary Toronto SPV safety supports further evaluation; leaves open long-term durability and comparative trials.
From November 1992 to March 1993 fourteen patients received the Toronto SPV stentless porcine xenograft as aortic valve replacement. Median age was 56 years (range 32-70 years). 7 patients were male and 7 female. Implanted valve sizes ranged from 23 mm to 29 mm, the majority of patients received valves with 27 and 29 mm tissue diameter. A learning process was evident by aortic crossclamp time decreasing with experience. No valve-related mortality or morbidity occurred. Postoperatively echocardiography showed near normal valve performance in most patients. The longevity of the valve, however, still has to be established. Meanwhile we continue the implant of stentless bioprostheses as aortic valve substitutes in selected patients.
No takes yet. Share an insight, caveat, or question.
Konertz et al. (1994) conducted an observational in Aortic valve disease requiring replacement (n=14). Toronto SPV stentless porcine xenograft was evaluated on Valve-related mortality or morbidity. Aortic valve replacement using the Toronto SPV stentless porcine xenograft in 14 patients resulted in 0% valve-related mortality or morbidity and near normal postoperative valve performance.
Synapse has enriched 10 related papers. Consider them for comparative context: